ReviewHuman vaccines & immunotherapeutics2017
Current prospects and future challenges for nasal vaccine delivery.
Review in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed.
- A Double-Edged Sword: Breast Milk-Derived Maternal Antibodies and Infant Vaccine Responses: A Narrative Review.Vaccines · 2026Review
- Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities.NPJ vaccines · 2026Review
- Tracking spatio-temporal dynamics of early immune responses to an intranasal OMV-based pneumococcal vaccine candidate in mice.NPJ vaccines · 2026Article
- Intranasal unadjuvanted LcrV boosts parental Yersinia OMV primed lung immunity against pneumonic plague in mice.Nature communications · 2026Article
- Engineering a medical device for intranasal immunisation: ensuring targeted delivery and formulation stability.Frontiers in drug delivery · 2026Article
- Immunization with virus-like vesicle-based COVID-19 vaccine induces robust systemic and mucosal immunity.NPJ vaccines · 2025Article
- Review
- Deconvolution of cargo delivery and immunogenicity following intranasal delivery of mRNA lipid nanoparticle vaccines.Molecular therapy. Nucleic acids · 2025Article
- Targeting Respiratory Viruses: The Efficacy of Intranasal mRNA Vaccination in Generating Protective Mucosal and Systemic Immunity Against Influenza A (H1N1).Influenza and other respiratory viruses · 2025Article
- Product and trial design considerations on the path towards a vaccine to combat opioid overdose.NPJ vaccines · 2025Review
- Nanotechnology-driven advances in intranasal vaccine delivery systems against infectious diseases.Frontiers in immunology · 2025Review
- Estradiol enhances B cell humoral immune responses against genital herpes simplex virus type 2 in mice through an IL-17 dependant pathway.Frontiers in immunology · 2025Article
- Review
- Intranasal boosting with RBD-HR protein vaccine elicits robust mucosal and systemic immune responses.Genes & diseases · 2024Article
- Acceptance of New Respiratory Syncytial Virus Vaccine among Pregnant Women in Nepal for Future Routine Immunization: A Descriptive Crosssectional Study.JNMA; journal of the Nepal Medical Association · 2024Article
- Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model.Microbiology spectrum · 2024Article
- Polymeric Nanoparticles as Oral and Intranasal Peptide Vaccine Delivery Systems: The Role of Shape and Conjugation.Vaccines · 2024Article
- Spray Drying of Bacterial Membrane Vesicles for Vaccine Delivery.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Mucosal vaccination with outer membrane vesicles derived fromFrontiers in immunology · 2024Article
- From intramuscular to nasal: unleashing the potential of nasal spray vaccines against coronavirus disease 2019.Clinical & translational immunology · 2024Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasal delivery offers many benefits over traditional approaches to vaccine administration. These include ease of administration without needles that reduces issues associated with needlestick injuries and disposal. Additionally, this route offers easy access to a key part of the immune system that can stimulate other mucosal sites throughout the body. Increased acceptance of nasal vaccine products in both adults and children has led to a burgeoning pipeline of nasal delivery technology. Key challenges and opportunities for the future will include translating in vivo data to clinical outcomes. Particular focus should be brought to designing delivery strategies that take into account the broad range of diseases, populations and healthcare delivery settings that stand to benefit from this unique mucosal route.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.